High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation

References

• Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217–222.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcome. Int j Radiat Oncol Biol Phys. 2008;15(71):1028–1033.
   Google Scholar
• Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–473.
   PubMed Web of Science ®Google Scholar
• Mahmood U, Levy LB, Nguyen PL, et al. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014;192(6):1650–1656.
   PubMed Web of Science ®Google Scholar
• Ávila M, Patel L, López S, et al. Patient-reported outcomes after treatment for clinically localized prostate cancer: a systematic review and Meta-analysis. Cancer Treat Rev. 2018;66:23–44.
   PubMed Web of Science ®Google Scholar
• Taylor JM, Chen VE, Miller RC, et al. The impact of prostate cancer treatment on quality of life: a narrative review with a focus on randomized data. Res Rep Urol. 2020;12(12):533–546.
   PubMedGoogle Scholar
• Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of Treatment-Related morbidity for a randomized trial comparing a Low-Dose-Rate brachytherapy boost with a Dose-Escalated external beam boost for high- and Intermediate-Risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):286–295.
   PubMed Web of Science ®Google Scholar
• Kälkner KM, Wahlgren T, Ryberg M, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol. 2007;46(7):909–917.
   PubMed Web of Science ®Google Scholar
• Hjälm-Eriksson M, Nilsson S, Brandberg Y, et al. High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single Centre experience. Acta Oncol. 2021;60(10):1301–1307.
   PubMed Web of Science ®Google Scholar
• Cohn-Cedermark G, Hjälm-Eriksson M, Castellanos, et al. The frequency of side effects among patients with localized prostate cancer treated with combined external radiotherapy and HDR 192-Iridium brachytherapy boost decreases with number of treated patients; An effect of the learning curve. Poster session, European Society for Therapeutic Radiology and Oncology ESTRO 27, Annual conference, 2008 Sept 14-18, Gothenburg, Sweden.
   Google Scholar
• Wahlgren T, Nilsson S, Lennernas B, et al. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69(3):662–670.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800–804.
   Google Scholar
• Delahunt B, Egevad L, Samaratunga H, et al. Review. Gleason and fuhrman no longer make the grade. Histopathology. 2016;68(4):475–481.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind CH, editors. International union against cancer. TNM classification of malignant tumours. 5th ed. New York (NY), John Wiley & Sons, 1997.
   Google Scholar
• Michelson H, Bolund C, Nilsson B, et al. Health-related quality of life measured by the EORTC QLQ-C30—reference values from a large sample of swedish population. Acta Oncol. 2000;39(4):477–484.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The european organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Van Andel G, Bottomley A, Fossa SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Can. 2008;44(16):2418–2424.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual 3rd Edition. Brussel (BE) European Organisation for Research and Treatment of Cancer, 2001.
   Google Scholar
• Galalae RM, Loch T, Riemer B, et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther Onkol. 2004;180(9):582–589.
   PubMed Web of Science ®Google Scholar
• Joly F, Brune D, Couette JE, et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol. 1998;9(7):751–757.
   PubMed Web of Science ®Google Scholar
• Huang-Tiel HJ, Otto I, Golka K, et al. Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer. Investig Clin Urol. 2020;61(3):250–259.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Rojas JA, Ostler MJ, et al. Quality of life after radical radiotherapy for prostate cancer: Longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy. Clin Oncol (R Coll Radiol). 2013;25(5):321–327.
   PubMed Web of Science ®Google Scholar
• Morgan TM, Press RH, Cutrell PK, et al. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. J Contemp Brachytherapy. 2018;10(6):495–502.
   PubMed Web of Science ®Google Scholar
• Shahid N, Loblaw A, Chung HT, et al. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer. J Clin. Oncol. 2017;29(7):412–420.
   Google Scholar
• Sprangers MAG, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507–1515.
   PubMed Web of Science ®Google Scholar
• Fransson P, Nilsson P, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021;22(2):235–245.
   PubMed Web of Science ®Google Scholar
• Staffurth JN, Haviland JS, Wilkins A, CHHiP Trial Management Group, et al. Impact of hypofractionated radiotherapy on patient reported outcomes in prostate cancer: Results up to 5 year in the CHHiP trial (CRUK/06/016). J. Eur Urol Oncol. 2021;4(6):980–992.
   PubMed Web of Science ®Google Scholar
• Wortel RC, Oomen-de Hoop E, Heemsbergen WD, et al. Moderate hypofractionation in intermediate- and High-Risk, localized prostate cancer: Health-Related quality of life from the randomized, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2019;103(4):823–833.
   PubMed Web of Science ®Google Scholar
• Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term follow up. J Urol. 2010;183(6):2206–2212.
   PubMed Web of Science ®Google Scholar
• Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306(11):1205–1214.
   PubMed Web of Science ®Google Scholar
• Roeloffzen EM, Lips IM, Van Gellekom MP, et al. Health-related quality of life up to six years after (125) I brachytherapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(4):1054–1060.
   PubMed Web of Science ®Google Scholar
• Hollenbeck BK, Wei JT, Sanda MG, et al. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. J. Urology. 2004;63(5):946–950.
   PubMed Web of Science ®Google Scholar
• Fransson P, Widmark A. Does one have a sexual life 15 years after external beam radiotherapy for prostate-cancer? Prospective patient-reported outcome of sexual function, a comparison with age-matched controls. Urol Oncol. 2011;29(2):137–144.
   PubMed Web of Science ®Google Scholar
• Wahlgren T, Nilsson S, Ryberg M, et al. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity. Acta Oncol. 2005;44(6):633–643.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in Health-Related quality-of-Life scores. J Clin Oncol. 1998;16(1):139–144.
   PubMed Web of Science ®Google Scholar